import streamlit as st
import google.generativeai as genai

# --- ğŸ¥ å©¦ç™Œè‡¨åºŠå°èˆªèˆ‡å¯¦è­‰åœ–æ›¸é¤¨ (2026 æœ€çµ‚å…¨æ–¹ä½æ•´åˆç‰ˆ) ---
st.set_page_config(page_title="å©¦ç™Œè‡¨åºŠè©¦é©—å°èˆªç³»çµ±", layout="wide")

st.markdown("""
    <style>
    @import url('https://fonts.googleapis.com/css2?family=Noto+Sans+TC:wght@400;700;900&family=Roboto:wght@400;700;900&display=swap');
    
    /* === æ¥µè‡´ç·Šç·»åŒ– UI === */
    html, body, [class*="css"] {
        font-family: 'Noto Sans TC', 'Roboto', sans-serif;
        background-color: #F4F7F9;
        color: #1A1A1A;
        font-size: 19px !important;
        line-height: 1.1;
    }

    .main-title {
        font-size: 30px !important; font-weight: 900; color: #004D40;
        padding: 5px 0; border-bottom: 3px solid #4DB6AC; margin-bottom: 5px;
    }

    .big-stage-card {
        border-radius: 10px; padding: 0px; 
        box-shadow: 0 2px 10px rgba(0,0,0,0.08);
        border: 2px solid transparent; background: white; 
        margin-bottom: 4px; overflow: hidden; height: auto !important;
    }
    .big-stage-header {
        font-size: 17px !important; font-weight: 900; color: white;
        padding: 5px; text-align: center;
    }

    .sub-block {
        margin: 2px 4px; padding: 4px;
        border-radius: 6px; background: #F8F9FA;
        border-left: 5px solid #546E7A;
    }
    .sub-block-title {
        font-size: 13px; font-weight: 900; color: #37474F;
        margin-bottom: 1px; border-bottom: 1.1px solid #CFD8DC; padding-bottom: 1px;
    }
    .sub-block-content {
        font-size: 14px; color: #263238; font-weight: 500; line-height: 1.15;
    }

    /* éšæ®µé…è‰² */
    .card-p-tx { border-color: #2E7D32; }
    .header-p-tx { background: linear-gradient(135deg, #43A047, #2E7D32); }
    .card-p-mt { border-color: #1565C0; }
    .header-p-mt { background: linear-gradient(135deg, #1E88E5, #1565C0); }
    .card-r-tx { border-color: #E65100; }
    .header-r-tx { background: linear-gradient(135deg, #FB8C00, #E65100); }
    .card-r-mt { border-color: #6A1B9A; }
    .header-r-mt { background: linear-gradient(135deg, #8E24AA, #6A1B9A); }

    /* æŒ‰éˆ•æ¨£å¼ï¼šæ·±é»‘è‰²åŠ ç²— (#1A1A1A) ç¢ºä¿å­—é«”æ¸…æ™° */
    .stPopover button { 
        font-weight: 900 !important; font-size: 12px !important; 
        border-radius: 4px !important; margin-top: 1px !important;
        padding: 1px 6px !important; width: 100% !important; 
        text-align: left !important; color: #1A1A1A !important; 
        border: 1px solid rgba(0,0,0,0.15) !important;
        box-shadow: 0 1px 3px rgba(0,0,0,0.1) !important;
    }
    
    .stPopover button[aria-label*="ğŸ“š"] { background: #ECEFF1 !important; border-left: 5px solid #455A64 !important; }
    .stPopover button[aria-label*="Eli Lilly"] { background: #FCE4EC !important; border-left: 5px solid #E91E63 !important; } 
    .stPopover button[aria-label*="Daiichi Sankyo"] { background: #E8F5E9 !important; border-left: 5px solid #4CAF50 !important; } 
    .stPopover button[aria-label*="MSD"] { background: #E3F2FD !important; border-left: 5px solid #1976D2 !important; } 
    .stPopover button[aria-label*="AstraZeneca"] { background: #F3E5F5 !important; border-left: 5px solid #8E24AA !important; } 
    .stPopover button[aria-label*="GSK"] { background: #FFF3E0 !important; border-left: 5px solid #F57C00 !important; } 
    .stPopover button[aria-label*="Gilead"] { background: #E1F5FE !important; border-left: 5px solid #03A9F4 !important; } 

    .detail-section { background: white; border-radius: 18px; padding: 25px; border: 1px solid #CFD8DC; box-shadow: 0 10px 40px rgba(0,0,0,0.05); }
    .hr-big-val { font-family: 'Roboto', sans-serif; font-size: 48px !important; font-weight: 900; color: #D84315; }
    </style>
    """, unsafe_allow_html=True)

# --- 1. æŒ‡å¼•å°èˆªæ•¸æ“šåº«ï¼šåŒ…å« MOCã€PSOC/PROC åˆ†æµèˆ‡å­å®®é ¸ç™Œ ---
guidelines_nested = {
    "Endometrial": [
        {"id": "P-TX", "header": "åˆæ²» (Primary Tx)", "css": "p-tx", "subs": [
            {"title": "MMRd / MSI-H / dMMR", "content": "ä¸€ç·šé¦–é¸ï¼šChemo + PD-1 (GY018/RUBY)ã€‚Dostarlimab ç²ç›Šæ¥µé¡¯è‘—ã€‚"},
            {"title": "NSMP / pMMR / MSS", "content": "æ’é™¤åˆ†å‹ã€‚è¦– ER/Grade æ¬Šé‡æ±ºç­–ï¼›äºŒç·šè€ƒæ…® Pembro+Lenvaã€‚"},
            {"title": "POLEmut / p53abn", "content": "POLE: æœ€ä½³é å¾Œå¯é™éšï¼›p53abn: æœ€å·®é å¾Œï¼Œéœ€ç©æ¥µåŒ–æ”¾ç™‚ã€‚"}]},
        {"id": "P-MT", "header": "ä¸€ç·šç¶­æŒ (1L Maint)", "css": "p-mt", "subs": [{"title": "IO Maintenance", "content": "ä¸€ç·š IO æ²»ç™‚å¾Œæ¥çºŒç¶­æŒç›´åˆ°ç–¾ç—…é€²å±• (PD)ã€‚"}]},
        {"id": "R-TX", "header": "å¾©ç™¼æ²»ç™‚ (Recurr Tx)", "css": "r-tx", "subs": [{"title": "Recurrent EC", "content": "äºŒç·šæ–¹æ¡ˆï¼šæ¨™é¶+å…ç–« (pMMR) æˆ– IO å–®è—¥ (MMRd/GARNET)ã€‚"}]},
        {"id": "R-MT", "header": "å¾©å¾Œç¶­æŒ (PR-Maint)", "css": "r-mt", "subs": [{"title": "Continuous Therapy", "content": "ç¶­æŒæœ‰æ•ˆæ²»ç™‚ç›´åˆ°ä¸å¯è€å—æˆ–é€²å±•ã€‚"}]}
    ],
    "Ovarian": [
        {"id": "P-TX", "header": "åˆæ²» (Primary Tx)", "css": "p-tx", "subs": [
            {"title": "HGSC / Endometrioid", "content": "æ‰‹è¡“ (PDS/IDS) + Carboplatin/Paclitaxel Â± Bevacizumabã€‚"},
            {"title": "Mucinous (MOC) é‘‘åˆ¥", "content": "åˆ¤å®šï¼šCK7+/SATB2- (åŸç™¼)ã€‚1. Expansile: é å¾Œä½³ã€‚ 2. Infiltrative: é«˜å¾©ç™¼é¢¨éšªï¼Œå»ºè­°ç©æ¥µåŒ–ç™‚ã€‚"}]},
        {"id": "P-MT", "header": "ä¸€ç·šç¶­æŒ (1L Maint)", "css": "p-mt", "subs": [
            {"title": "BRCA mutated", "content": "Olaparib å–®è—¥ç¶­æŒ 2å¹´ã€‚"}, {"title": "HRD positive (wt)", "content": "Olaparib+Bev (2å¹´) æˆ– Niraparib å–®è—¥ (3å¹´)ã€‚"}]},
        {"id": "R-TX", "header": "å¾©ç™¼æ²»ç™‚ (R-TX)", "css": "r-tx", "subs": [
            {"title": "PSOC (PFI > 6m)", "content": "é‰‘é¡æ•æ„Ÿã€‚å«é‰‘é›™è—¥åŒ–ç™‚ Â± Bevã€‚è©•ä¼°äºŒæ¬¡æ‰‹è¡“ç²ç›Šã€‚"},
            {"title": "PROC (PFI < 6m)", "content": "é‰‘é¡æŠ—è—¥ã€‚å–®è—¥åŒ–ç™‚ Â± Bev æˆ–æ¨™é¶ ADC (MIRASOL)ã€‚"}]},
        {"id": "R-MT", "header": "å¾©å¾Œç¶­æŒ (PR-Maint)", "css": "r-mt", "subs": [{"title": "Platinum Sensitive Maint", "content": "æ•‘æ´ç·©è§£å¾ŒçºŒä»¥ PARPi ç¶­æŒæ²»ç™‚ã€‚"}]}
    ],
    "Cervical": [
        {"id": "P-TX", "header": "åˆæ²» (Primary Tx)", "css": "p-tx", "subs": [
            {"title": "CCRT (Locally Advanced)", "content": "åŒæ­¥åŒ–æ”¾ç™‚ã€‚é«˜é¢¨éšªè€…åŒæ­¥ IO (A18) æˆ–èª˜å°åŒ–ç™‚ (INTERLACE)ã€‚"},
            {"title": "Early Stage (Surgery)", "content": "é–‹è…¹æ ¹æ²»è¡“ (LACC)ã€‚ä½é¢¨éšªè€…é¸å–®ç´”åˆ‡é™¤ (SHAPE)ã€‚"}]},
        {"id": "P-MT", "header": "ä¸€ç·šç¶­æŒ (1L Maint)", "css": "p-mt", "subs": [{"title": "Metastatic Maint", "content": "1L è½‰ç§»æ€§ IO æ–¹æ¡ˆå¾Œå»¶çºŒç¶­æŒè‡³é€²å±•ã€‚"}]},
        {"id": "R-TX", "header": "å¾©ç™¼æ²»ç™‚ (Recurr Tx)", "css": "r-tx", "subs": [
            {"title": "Recurrent / Metastatic", "content": "ä¸€ç·š Pembro + åŒ–ç™‚ Â± Bevã€‚äºŒç·š ADC (Tivdak) æˆ– IO (EMPOWER)ã€‚"}]},
        {"id": "R-MT", "header": "å¾©å¾Œç¶­æŒ (PR-Maint)", "css": "r-mt", "subs": [{"title": "Continuous Therapy", "content": "ç¶­æŒæœ‰æ•ˆæ²»ç™‚ç›´è‡³é€²å±•ã€‚"}]}
    ]
}

# --- 2. å¯¦è­‰é‡Œç¨‹ç¢‘ (ğŸ“š Milestone Library - å®Œæ•´ 24 é …æ·±åº¦æ“´å……) ---
milestone_db = [
    # å­å®®å…§è†œç™Œ
    {"cancer": "Endometrial", "pos": "P-TX", "sub_pos": ["MMRd / MSI-H / dMMR"], "name": "ğŸ“š RUBY (Dostarlimab)", "type": "Milestone", "drug": "Dostarlimab + CP", "summary": "FIGO III-IV/Recurrentã€‚dMMR æ­»äº¡é¢¨éšªé™ 68% (HR 0.32)ï¼›å…¨äººç¾¤ mOS 44.6m vs 28.2m (HR 0.69, P<0.001)ã€‚ORR é¡¯è‘—æå‡ã€‚", "details": "é‡Œç¨‹ç¢‘ç ”ç©¶ï¼šç¢ºç«‹ä¸€ç·š dMMR å…ç–«+åŒ–ç™‚ä¹‹æ¨™æº–åœ°ä½ã€‚"},
    {"cancer": "Endometrial", "pos": "P-TX", "sub_pos": ["MMRd / MSI-H / dMMR", "NSMP / pMMR / MSS"], "name": "ğŸ“š NRG-GY018", "type": "Milestone", "drug": "Pembrolizumab + CP", "summary": "dMMR æ—ç¾¤ PFS HR 0.30ï¼›pMMR äº¦é¡¯è‘—æ”¹å–„ (HR 0.54)ã€‚FDA æ–¼ 2024 å…¨é¢æ ¸å‡†æ‰€æœ‰ MMR ç‹€æ…‹é©æ‡‰ç—‡ã€‚", "details": "æ“´å¤§ä¸€ç·šå…ç–«ç²ç›Šè‡³å…¨äººç¾¤ã€‚"},
    {"cancer": "Endometrial", "pos": "P-TX", "sub_pos": ["NSMP / pMMR / MSS"], "name": "ğŸ“š DUO-E", "type": "Milestone", "drug": "Durvalumab Â± Olaparib", "summary": "PFS æ”¹å–„ï¼šä¸‰è—¥çµ„ HR 0.57 (vs CP)ï¼›å–®è—¥ IO çµ„ HR 0.77ã€‚æç¤º PARPi èˆ‡ IO åœ¨ pMMR çš„ç¶­æŒå”åŒæ•ˆæ‡‰ã€‚", "details": "å»ºç«‹ã€Œå…ç–«+ç¶­æŒã€ç­–ç•¥ã€‚"},
    {"cancer": "Endometrial", "pos": "P-TX", "sub_pos": ["MMRd / MSI-H / dMMR"], "name": "ğŸ“š AtTEnd", "type": "Milestone", "drug": "Atezolizumab + CP", "summary": "dMMR ç²ç›Šé¡¯è‘— (HR 0.36)ï¼›å…¨äººç¾¤ OS HR 0.82 (é‚Šç·£é¡¯è‘—)ã€‚å«æœ‰ç´„ 10% ç™Œè‚‰ç˜¤æ—ç¾¤ã€‚", "details": "æ”¯æŒä¸€ç·š PD-(L)1 è­‰æ“šéˆã€‚"},
    {"cancer": "Endometrial", "pos": "R-TX", "sub_pos": ["Recurrent EC"], "name": "ğŸ“š KEYNOTE-775", "type": "Milestone", "drug": "Lenvatinib + Pembro", "summary": "äºŒç·š(æ›¾å«é‰‘) pMMRï¼šOS 17.4m vs 12.0m (HR 0.68)ï¼›5å¹´ OS ç‡ 16.7% vs 7.3%ã€‚", "details": "ç¢ºç«‹äºŒç·šæ¨™æº–ï¼Œä½†éœ€é‡è¦–æ¯’æ€§ç®¡ç† (å¦‚é«˜è¡€å£“ã€ç–²å‹)ã€‚"},
    {"cancer": "Endometrial", "pos": "R-TX", "sub_pos": ["Recurrent EC"], "name": "ğŸ“š GARNET", "type": "Milestone", "drug": "Dostarlimab (å–®è‡‚)", "summary": "dMMR/MSI-H ORR é” 45.5%ï¼Œåæ‡‰æŒä¹…ã€‚ä¸­ä½åæ‡‰æŒçºŒæ™‚é–“ (DOR) æœªé”åˆ°ã€‚", "details": "å¥ å®šå¾Œç·šå…ç–«å–®è—¥åŠ é€Ÿæ ¸å‡†ä¹‹åŸºç¤ã€‚"},

    # å­å®®é ¸ç™Œ
    {"cancer": "Cervical", "pos": "P-TX", "sub_pos": ["CCRT (Locally Advanced)"], "name": "ğŸ“š KEYNOTE-A18", "type": "Milestone", "drug": "Pembrolizumab + CCRT", "summary": "å±€éƒ¨æ™šæœŸã€‚36å€‹æœˆ OS 82.6% vs 74.8% (HR 0.67)ã€‚PFS åŒæ™‚é¡¯è‘—ç²ç›Šã€‚", "details": "LACC é«˜é¢¨éšªç¾¤ä¹‹æ–°æ¨™ç«¿æ²»ç™‚ã€‚"},
    {"cancer": "Cervical", "pos": "P-TX", "sub_pos": ["CCRT (Locally Advanced)"], "name": "ğŸ“š INTERLACE", "type": "Milestone", "drug": "Induction Chemo (6wk)", "summary": "èª˜å°åŒ–ç™‚ï¼š5å¹´ OS 80% vs 72% (HR 0.60)ã€‚5å¹´ PFS 72% vs 64% (HR 0.65)ã€‚", "details": "ç¾æˆè€è—¥åƒ¹å€¼ï¼šCarbo/Pacli é€±ç™‚å¤§å¹…æ”¹å–„ç”Ÿå­˜ã€‚"},
    {"cancer": "Cervical", "pos": "P-TX", "sub_pos": ["CCRT (Locally Advanced)"], "name": "ğŸ“š CALLA (é™°æ€§)", "type": "Milestone", "drug": "Durvalumab + CCRT", "summary": "å±€éƒ¨æ™šæœŸã€‚æ•´é«”æœªé”çµ±è¨ˆå­¸ PFS æ”¹å–„ã€‚HR 0.84ã€‚", "details": "æç¤ºå…ç–«èˆ‡æ”¾åŒ–ç™‚çµ„åˆä»éœ€æ›´ç²¾æº–æ—ç¾¤è­˜åˆ¥ã€‚"},
    {"cancer": "Cervical", "pos": "R-TX", "sub_pos": ["1L Recurrent"], "name": "ğŸ“š KEYNOTE-826", "type": "Milestone", "drug": "Pembro + Chemo Â± Bev", "summary": "æŒçºŒ/å¾©ç™¼ä¸€ç·šã€‚å…¨äººç¾¤ OS HR 0.63ï¼›CPSâ‰¥1 HR 0.60ã€‚æ”¯æŒä¸€ç·šå…ç–«å…¨é¢ä»‹å…¥ã€‚", "details": "R/M ä¸€ç·šæ ¸å¿ƒæ¨™æº–ã€‚"},
    {"cancer": "Cervical", "pos": "R-TX", "sub_pos": ["1L Recurrent"], "name": "ğŸ“š BEATcc", "type": "Milestone", "drug": "Atezolizumab + Chemo+Bev", "summary": "ä¸€ç·š R/Mã€‚mPFS 13.7m vs 10.4m (HR 0.62)ï¼›OS HR 0.68ã€‚", "details": "æä¾›ä¸€ç·šå…ç–«ä½µç”¨æ–°é¸é …ã€‚"},
    {"cancer": "Cervical", "pos": "R-TX", "sub_pos": ["2L / 3L Therapy"], "name": "ğŸ“š EMPOWER-Cx 1", "type": "Milestone", "drug": "Cemiplimab", "summary": "äºŒç·š(æ›¾å«é‰‘)ã€‚OS 12.0m vs 8.5m (HR 0.69)ï¼›ç²ç›Šä¸ä¾è³´ PD-L1 è¡¨ç¾ã€‚", "details": "å¾Œç·šå…ç–«å–®è—¥ä¹‹é—œéµæ•¸æ“šã€‚"},
    {"cancer": "Cervical", "pos": "R-TX", "sub_pos": ["2L / 3L Therapy"], "name": "ğŸ“š innovaTV 301", "type": "Milestone", "drug": "Tisotumab Vedotin (ADC)", "summary": "äºŒ/ä¸‰ç·šã€‚OS 11.5m vs 9.5m (HR 0.70)ï¼ŒORR 17.8% vs 5.2%ã€‚", "details": "ADC é€²å…¥æ¨™æº–å¾Œç·šã€‚éœ€æ³¨æ„çœ¼è¡¨ã€ç¥ç¶“èˆ‡å‡ºè¡€å‰¯ä½œç”¨ã€‚"},
    {"cancer": "Cervical", "pos": "P-TX", "sub_pos": ["Early Stage (Surgery)"], "name": "ğŸ“š SHAPE", "type": "Milestone", "drug": "Simple Hysterectomy", "summary": "æ—©æœŸä½é¢¨éšªã€‚3å¹´éª¨ç›†å¾©ç™¼ç‡ 2.5% vs 2.2% (ä¸åŠ£æ€§é”æˆ)ã€‚å‰¯ä½œç”¨é¡¯è‘—é™ä½ã€‚", "details": "æ”¯æŒæ‰‹è¡“é™éšï¼šæ—©æœŸä½é¢¨éšªå¯å…æ–¼æ ¹æ²»è¡“ã€‚"},

    # åµå·¢ç™Œ
    {"cancer": "Ovarian", "pos": "P-MT", "sub_pos": ["BRCA mutated"], "name": "ğŸ“š SOLO-1 (Olaparib)", "type": "Milestone", "drug": "Olaparib ç¶­æŒ", "summary": "ä¸€ç·šç¶­æŒã€‚7å¹´ survival 67% (vs 46.5%, HR 0.33)ï¼›mPFS æœªé”åˆ° vs 13.8mã€‚", "details": "ç¢ºç«‹ BRCAm æ‚£è€…å…·å‚™è‡¨åºŠæ²»ç™’ä¹‹å¯èƒ½æ€§ã€‚"},
    {"cancer": "Ovarian", "pos": "P-MT", "sub_pos": ["HRD positive (wt)", "HRD negative / pHRD"], "name": "ğŸ“š PRIMA", "type": "Milestone", "drug": "Niraparib ç¶­æŒ", "summary": "ä¸€ç·šç¶­æŒã€‚æ•´é«” PFS HR 0.62ï¼›HRD+ ç²ç›Šæœ€å¤§ (HR 0.43)ã€‚5å¹´ç„¡æƒ¡åŒ–ç‡ 35% vs 16%ã€‚", "details": "æ”¯æŒä¸é™ BRCA ä¹‹ä¸€ç·šç¶­æŒæ¦‚å¿µã€‚"},
    {"cancer": "Ovarian", "pos": "P-MT", "sub_pos": ["HRD positive (wt)"], "name": "ğŸ“š PAOLA-1", "type": "Milestone", "drug": "Olaparib + Bev", "summary": "ä¸€ç·šç¶­æŒã€‚HRD+ æ—ç¾¤ 5å¹´ OS ç‡ 75.2% vs 58.3% (HR 0.62)ã€‚", "details": "ç¢ºç«‹ã€ŒPARPi + anti-VEGFã€ç‚º HRD+ ç¶­æŒè·¯å¾‘ã€‚"},
    {"cancer": "Ovarian", "pos": "P-MT", "sub_pos": ["BRCA mutated", "HRD positive (wt)"], "name": "ğŸ“š ATHENAâ€“MONO", "type": "Milestone", "drug": "Rucaparib ç¶­æŒ", "summary": "ä¸€ç·šç¶­æŒã€‚ITT PFS HR 0.52 (28.7m vs 11.3m)ï¼›HRD+ HR 0.47ã€‚", "details": "æ“´å…… PARPi ä¸€ç·šç¶­æŒè­‰æ“šéˆã€‚"},
    {"cancer": "Ovarian", "pos": "R-MT", "sub_pos": ["Platinum Sensitive Maint"], "name": "ğŸ“š NOVA", "type": "Milestone", "drug": "Niraparib ç¶­æŒ", "summary": "å¾©ç™¼ç¶­æŒã€‚gBRCA HR 0.27ï¼›é gBRCA HR 0.45ã€‚é¡¯è‘—å»¶ç·©ç–¾ç—…é€²å±•ã€‚", "details": "å¾©ç™¼ç¶­æŒä¹‹æ ¸å¿ƒåŸºçŸ³ç ”ç©¶ã€‚"},
    {"cancer": "Ovarian", "pos": "R-MT", "sub_pos": ["Platinum Sensitive Maint"], "name": "ğŸ“š ARIEL3", "type": "Milestone", "drug": "Rucaparib ç¶­æŒ", "summary": "å¾©ç™¼ç¶­æŒã€‚Rucaparib åœ¨æ‰€æœ‰åˆ†å±¤(BRCA/HRD+/ITT)å‡ PFS æ”¹å–„ã€‚", "details": "æä¾›é‰‘é¡æ•æ„Ÿå¾©ç™¼å¾Œä¹‹äºŒç·šç¶­æŒé¸é …ã€‚"},
    {"cancer": "Ovarian", "pos": "R-MT", "sub_pos": ["Platinum Sensitive Maint"], "name": "ğŸ“š SOLO2", "type": "Milestone", "drug": "Olaparib ç¶­æŒ", "summary": "å¾©ç™¼ç¶­æŒ(BRCA)ã€‚OS 51.7m vs 38.8m (HR 0.74)ã€‚é•·æœŸç”Ÿå­˜ç²ç›Šé¡¯è‘—ã€‚", "details": "BRCA è®Šç•°å¾©ç™¼ç¶­æŒä»£è¡¨æ€§æ•¸æ“šã€‚"},
    {"cancer": "Ovarian", "pos": "P-MT", "sub_pos": ["HRD positive (wt)"], "name": "ğŸ“š DUO-O", "type": "Milestone", "drug": "Durva+Ola+Bev", "summary": "ä¸€ç·šçµ„åˆã€‚HRD+ çµ„ PFS é¡¯è‘—ç²ç›Š (HR 0.49)ã€‚IO éœ€çµ„åˆ PARPi/VEGF è¼ƒå…·æ½›åŠ›ã€‚", "details": "åµå·¢ç™Œå…ç–«ä¹‹çªç ´æ€§çµ„åˆè¨­è¨ˆã€‚"},
    {"cancer": "Ovarian", "pos": "R-TX (PROC)", "sub_pos": ["Platinum-Resistant"], "name": "ğŸ“š MIRASOL (FRÎ± ADC)", "type": "Milestone", "drug": "Mirvetuximab", "summary": "å¾Œç·š(PROC)ã€‚OS 16.4m vs 12.7m (HR 0.67)ï¼›PFS HR 0.65ï¼›ORR 42.3%ã€‚", "details": "é¦–å€‹è­‰æ˜ OS ç²ç›Šä¹‹ ADC ç ”ç©¶ï¼Œæ”¹è®ŠæŠ—è—¥å‹æ²»ç™‚æ¨™æº–ã€‚"},
    {"cancer": "Ovarian", "pos": "P-TX", "sub_pos": ["HGSC / Endometrioid"], "name": "ğŸ“š LION (NEJM 2019)", "type": "Milestone", "drug": "No Lymphadenectomy", "summary": "å®Œå…¨åˆ‡é™¤ä¸”è‡¨åºŠ LN é™°æ€§ï¼Œæ¸…æƒç„¡ç”Ÿå­˜ç²ç›Š (OS/PFS HR ~1.0) ä¸”ä½µç™¼ç—‡å¤šã€‚", "details": "æ”¯æŒé™ä½é†«æºæ€§å‚·å®³ï¼šè‡¨åºŠ LN é™°æ€§å…æ¸…æƒã€‚"},
]

# --- 3. æ‹›å‹Ÿä¸­è©¦é©— (ğŸ“ Ongoing - æ¥µé‡åŒ–ç´°ç¯€ + æ¨™è¨˜å„ªåŒ–) ---
ongoing_trials = [
    {"cancer": "Ovarian", "name": "FRAmework-01 (LY4170156)", "pharma": "Eli Lilly", "drug": "LY4170156 + Bevacizumab", "pos": "R-TX (PROC)", "sub_pos": ["Platinum-Resistant"], "type": "Ongoing",
     "rationale": "æ¨™é¶ Folate Receptor alpha (FRÎ±) ADCã€‚æ­è¼‰é¡å¾®ç®¡è›‹ç™½ Payloadã€‚é€éè¯ç”¨ Bevacizumab ç”¢ç”Ÿè¡€ç®¡é‡å¡‘å”åŒä½œç”¨ (Synergy)ï¼Œæå‡è—¥ç‰©æ»²é€æ·±åº¦ä¸¦é€éæ—è§€è€…æ•ˆæ‡‰æ®ºå‚·ä½è¡¨é”ç´°èƒï¼Œæ—¨åœ¨å…‹æœ PARPi è€è—¥å¾Œ PROC æ‚£è€…ä¹‹éœ€æ±‚ã€‚",
     "dosing": "å¯¦é©—çµ„ï¼šLY4170156 3mg/kg IV + Bevacizumab 15mg/kg IV Q3Wã€‚å°ç…§çµ„ï¼šé†«å¸«é¸æ“‡å–®è—¥åŒ–ç™‚ (Pacli, PLD, Gem) æˆ– MIRVã€‚",
     "inclusion": ["çµ„ç¹”å­¸ HG Serous / Carcinosarcoma åµå·¢ç™Œã€‚", "ç¶“ä¸­å¤®å¯¦é©—å®¤æª¢æ¸¬ç¢ºèª FRÎ± è¡¨é”é™½æ€§ã€‚", "æœ€å¾Œä¸€åŠ‘é‰‘é¡å¾Œ 90â€“180 å¤©å…§æƒ¡åŒ– (PROC)ã€‚", "å…ˆå‰æ¥å—é 1â€“3 ç·šç³»çµ±æ²»ç™‚ã€‚"],
     "exclusion": ["å…ˆå‰æ›¾ç”¨éå¸¶æœ‰ Topoisomerase I æŠ‘åˆ¶åŠ‘ Payload ä¹‹ ADC (å¦‚ Enhertu)ã€‚", "æ´»å‹•æ€§é–“è³ªæ€§è‚ºç—… (ILD) æˆ–éœ€é¡å›ºé†‡æ²»ç™‚ä¹‹è‚ºç‚ç—…å²ã€‚", "å…·æœ‰è‡¨åºŠé¡¯è‘—è›‹ç™½å°¿ (UPCR â‰¥ 2.0)ã€‚"], "ref": "NCT06536348"},
    
    {"cancer": "Ovarian", "name": "REJOICE-Ovarian01", "pharma": "Daiichi Sankyo", "drug": "R-DXd (Raludotatug Deruxtecan)", "pos": "R-TX (PROC)", "sub_pos": ["Platinum-Resistant"], "type": "Ongoing",
     "rationale": "æ¨™é¶ Cadherin-6 (CDH6) ADCï¼Œæ­è¼‰å¼·æ•ˆ DXd è¼‰è·ã€‚å…·å‚™æ¥µé«˜ DAR (8) èˆ‡å¼·åŠ›æ—è§€è€…æ•ˆæ‡‰ï¼Œå°ˆæ”»é«˜åº¦ç•°è³ªæ€§ä¹‹ PROC è…«ç˜¤ï¼Œè§£æ±ºå‚³çµ±åŒ–ç™‚åæ‡‰ç‡ä½è½ä¹‹ç“¶é ¸ã€‚",
     "dosing": "å¯¦é©—çµ„ï¼šR-DXd 5.6mg/kg IV Q3Wã€‚å°ç…§çµ„ï¼šç ”ç©¶è€…é¸æ“‡å–®è—¥åŒ–ç™‚ (Pacli, PLD, or Topo)ã€‚",
     "inclusion": ["çµ„ç¹”å­¸ HG Serous æˆ– Endometrioid PROCã€‚", "å…ˆå‰æ¥å— 1-4 ç·šç³»çµ±æ€§æ²»ç™‚ã€‚", "æä¾›ä¸­å¤®å¯¦é©—å®¤ CDH6 åˆ¤å®šåˆ¤å®šåˆ†å±¤ã€‚", "éœ€æ›¾ç”¨é Bevacizumabã€‚"],
     "exclusion": ["Low-grade / Clear cell / Mucinous (åŸç™¼)ã€‚", "åŸºç·š Grade â‰¥2 å‘¨é‚Šç¥ç¶“ç—…è®Šã€‚", "å¿ƒåŠŸèƒ½ä¸å…¨ (LVEF < 50%)ã€‚", "ILD/è‚ºéƒ¨ç—…å²ã€‚"], "ref": "JCO 2024"},
    
    {"cancer": "Ovarian", "name": "TroFuse-021", "pharma": "MSD", "drug": "Sac-TMT (MK-2870)", "pos": "P-MT", "sub_pos": ["HRD positive (wt)", "HRD negative / pHRD"], "type": "Ongoing",
     "rationale": "æ¨™é¶ Trop-2 ADCã€‚çµåˆ Beva å¾®ç’°å¢ƒèª¿ç¯€èˆ‡ ADC èª˜å°ä¹‹å…ç–«åŸæ€§ç´°èƒæ­»äº¡ (ICD) æ•ˆæ‡‰ï¼Œæ—¨åœ¨å„ªåŒ– pHRD/HRD+ æ—ç¾¤åœ¨ä¸€ç·šå«é‰‘åŒ–ç™‚å¾Œç¶­æŒç²ç›Šã€‚",
     "dosing": "å¯¦é©—è‡‚1ï¼šSac-TMT å–®è—¥ç¶­æŒã€‚å¯¦é©—è‡‚2ï¼šSac-TMT + Beva 15mg/kg Q3Wã€‚å°ç…§è‡‚ï¼šStandard Bevacizumab ç¶­æŒã€‚",
     "inclusion": ["æ–°è¨ºæ–· FIGO Stage III/IV åµå·¢/è¼¸åµç®¡ç™Œã€‚", "HRD ç‹€æ…‹ç”±ä¸­å¤®å¯¦é©—å®¤åˆ¤å®š (åŒ…å« pHRD)ã€‚", "ä¸€ç·šå«é‰‘åŒ–ç™‚å¾Œé” CR æˆ– PR ç‹€æ…‹ã€‚", "å¯ä¾›æª¢æ¸¬ä¹‹ Trop-2 çµ„ç¹”ã€‚"],
     "exclusion": ["BRCA çªè®Šã€‚", "å…ˆå‰ç”¨éé‡å° Trop-2 ä¹‹ ADC è—¥ç‰©ã€‚", "åš´é‡è‡ªé«”å…ç–«ç–¾ç—…æˆ– IBD ç—…å²ã€‚"], "ref": "ENGOT-ov85"},

    {"cancer": "Endometrial", "name": "MK2870-033", "pharma": "MSD", "drug": "Sac-TMT + Pembrolizumab", "pos": "P-MT", "sub_pos": ["IO Maintenance"], "type": "Ongoing",
     "rationale": "æ¨™é¶ Trop-2 ADC å”åŒ PD-1 æŠ‘åˆ¶åŠ‘ã€‚é€éå…ç–«é‡å¡‘æå‡ Pembrolizumab åœ¨ pMMR æˆ– NSMP æ—ç¾¤çš„æ‡‰ç­”æ·±åº¦èˆ‡æ‡‰ç­”ç‡ã€‚",
     "inclusion": ["pMMR å­å®®å…§è†œç™Œ (ä¸­å¿ƒæª¢æ¸¬)ã€‚", "FIGO III/IV ä¸€ç·šå«é‰‘+Pembroå¾Œé” CR/PRã€‚", "æœªé‡å°å¾©ç™¼é€²è¡Œéç³»çµ±æ€§æ²»ç™‚ã€‚"],
     "exclusion": ["å­å®®è‚‰ç˜¤ (Sarcoma)ã€‚", "å…ˆå‰æ¥å—éæ™šæœŸç³»çµ±æ€§ IO æ²»ç™‚ã€‚"], "ref": "ESMO 2025"},
    
    {"cancer": "Endometrial", "name": "GU-US-682-6769", "pharma": "Gilead", "drug": "SG (Trodelvy)", "pos": "R-TX", "sub_pos": ["Recurrent EC"], "type": "Ongoing",
     "rationale": "æ¨™é¶ Trop-2 ADCã€‚åˆ©ç”¨ SN-38 è¼‰è·å¼•ç™¼ DNA æå‚·ï¼Œå°ˆæ”»é‰‘é¡èˆ‡å…ç–«å¤±æ•—æ•‘æ´ï¼Œå…·å¼·åŠ› Bystander æ•ˆæ‡‰å°æŠ—ç•°è³ªæ€§ç—…ç¶ã€‚",
     "inclusion": ["å¾©ç™¼æ€§ EC (ä¸å«è‚‰ç˜¤)ã€‚", "é‰‘é¡èˆ‡ PD-1 å¤±æ•—å¾Œé€²å±•ã€‚", "å……åˆ†å™¨å®˜åŠŸèƒ½ (ANC â‰¥1500, PLT â‰¥100k)ã€‚"],
     "exclusion": ["å…ˆå‰ç”¨é Trop-2 ADCã€‚", "æ´»å‹•æ€§ CNS è½‰ç§»ã€‚"], "ref": "JCO 2024"},

    {"cancer": "Ovarian", "name": "DS8201-772 (Enhertu)", "pharma": "AstraZeneca", "drug": "T-DXd (Trastuzumab Deruxtecan)", "pos": "R-MT", "sub_pos": ["Platinum Sensitive Maint"], "type": "Ongoing",
     "rationale": "æ¨™é¶ HER2 ADCã€‚æ•‘æ´åŒ–ç™‚ç©©å®šå¾Œä¹‹ç²¾æº–ç¶­æŒé¦–é¸ã€‚è¶…é«˜ DAR (8) å„ªå‹¢æ¸…é™¤ HER2 è¡¨ç¾æ®˜ç•™ç—…ç¶ï¼Œå»¶é•·ç·©è§£æ™‚é–“ã€‚",
     "inclusion": ["HER2 IHC 1+/2+/3+ ç¢ºèªã€‚", "PSOC æ•‘æ´åŒ–ç™‚é”ç©©å®š (Non-PD)ã€‚", "LVEF â‰¥ 50%ã€‚"],
     "exclusion": ["æ›¾æ‚£æœ‰éœ€é¡å›ºé†‡æ²»ç™‚ä¹‹éæ„ŸæŸ“æ€§ ILD è‚ºéƒ¨ç—…å²ã€‚"], "ref": "JCO 2024"},

    {"cancer": "Ovarian", "name": "DOVE (APGOT-OV07)", "pharma": "GSK", "drug": "Dostarlimab + Bevacizumab", "pos": "R-TX (PROC)", "sub_pos": ["Platinum-Resistant"], "type": "Ongoing",
     "rationale": "é‡å°é€æ˜ç´°èƒç™Œ (OCCC)ã€‚åˆ©ç”¨ IO + anti-VEGF é›™é‡æ‰“æ“Šï¼Œæ”¹å–„å…¶ç‰¹æœ‰ä¹‹å…ç–«æŠ‘åˆ¶ç’°å¢ƒï¼Œèª˜ç™¼æ‡‰ç­”ã€‚",
     "inclusion": ["çµ„ç¹”å­¸ OCCC > 50%ã€‚", "é‰‘é¡æŠ—è—¥æ€§ (PFI < 12m)ã€‚", "RECIST v1.1 å¯æ¸¬é‡ç—…ç¶ã€‚"],
     "exclusion": ["å…ˆå‰ç”¨éä»»ä½•å…ç–«æ²»ç™‚ (PD-1/L1)ã€‚"], "ref": "JCO 2025"},

    {"cancer": "Cervical", "name": "innovaTV 301", "pharma": "Seagen", "drug": "Tisotumab Vedotin (Tivdak)", "pos": "R-TX", "sub_pos": ["2L / 3L Therapy"], "type": "Ongoing",
     "rationale": "æ¨™é¶ Tissue Factor (TF) ADCã€‚æ­è¼‰ MMAE è¼‰è·ï¼Œæ—¨åœ¨å…‹æœå¾Œç·šå­å®®é ¸ç™ŒåŒ–ç™‚è€è—¥æ€§ï¼Œæ”¹å–„ç”Ÿå­˜æœŸã€‚",
     "inclusion": ["å¾©ç™¼/è½‰ç§»å­å®®é ¸ç™Œã€‚", "å…ˆå‰æ¥å— 1â€“2 ç·šæ²»ç™‚å¾Œé€²å±•ã€‚"],
     "exclusion": ["åš´é‡çœ¼ç–¾æˆ–è§’è†œç‚ã€‚", "æ´»å‹•æ€§å‡ºè¡€é¢¨éšªã€‚"], "ref": "NEJM 2024"}
]

# --- 4. å‹•æ…‹æ¨¡å‹å·¡é‚é‚è¼¯ ---
def get_gemini_model():
    try:
        available_models = [m.name for m in genai.list_models() if 'generateContent' in m.supported_generation_methods]
        target_model = None
        for m in available_models:
            if 'gemini-1.5-flash' in m: target_model = m; break
        if not target_model:
            for m in available_models:
                if 'gemini-pro' in m or 'gemini-1.5-pro' in m: target_model = m; break
        if target_model: return genai.GenerativeModel(target_model)
    except: return None

# --- 5. å´é‚Šæ¬„ ---
if 'selected_trial' not in st.session_state:
    st.session_state.selected_trial = milestone_db[0]['name']

with st.sidebar:
    st.markdown("<h3 style='color: #6A1B9A;'>ğŸ¤– AI å¯¦è­‰æ±ºç­–åŠ©ç†</h3>", unsafe_allow_html=True)
    api_key = st.text_input("Gemini API Key", type="password")
    with st.expander("âœ¨ ç—…æ­·æ·±åº¦æ•¸æ“šæ¯”å°", expanded=True):
        p_notes = st.text_area("è¼¸å…¥æ‘˜è¦ (å«ç´°èƒå‹æ…‹/æ¨™è¨˜)", height=250)
        if st.button("ğŸš€ é–‹å§‹åˆ†æ"):
            if api_key and p_notes:
                try:
                    genai.configure(api_key=api_key)
                    model = get_gemini_model()
                    if model:
                        prompt = f"åˆ†æï¼š{p_notes}ã€‚åƒè€ƒå¯¦è­‰ï¼š{milestone_db} åŠé€²è¡Œä¸­ï¼š{ongoing_trials}ã€‚æä¾›è·¯å¾‘å»ºè­°èˆ‡ç†ç”±ã€‚"
                        st.write(model.generate_content(prompt).text)
                    else: st.error("æ‰¾ä¸åˆ°å¯ç”¨ AI æ¨¡å‹ã€‚")
                except Exception as e: st.error(f"AI ç•°å¸¸: {e}")

# --- 6. ä¸»é é¢ï¼šå°èˆªåœ°åœ– ---
st.markdown("<div class='main-title'>å©¦ç™Œè‡¨åºŠå°èˆªå„€è¡¨æ¿ (2026 å¯¦è­‰èˆ‡æ”¶æ¡ˆå…¨æ•´åˆ)</div>", unsafe_allow_html=True)
cancer_type = st.radio("ç¬¬ä¸€æ­¥ï¼šé¸æ“‡ç™Œç—‡é¡å‹", ["Endometrial", "Ovarian", "Cervical"], horizontal=True)

cols = st.columns(len(guidelines_nested[cancer_type]))
stages_data = guidelines_nested[cancer_type]

for i, stage in enumerate(stages_data):
    with cols[i]:
        st.markdown(f"""<div class='big-stage-card card-{stage['css']}'><div class='big-stage-header header-{stage['css']}'>{stage['header']}</div>""", unsafe_allow_html=True)
        for sub in stage['subs']:
            st.markdown(f"""<div class='sub-block'><div class='sub-block-title'>ğŸ“˜ {sub['title']}</div><div class='sub-block-content'>{sub['content']}</div>""", unsafe_allow_html=True)
            
            # A. é¡¯ç¤ºé‡Œç¨‹ç¢‘ (ğŸ“š)
            rel_milestones = [m for m in milestone_db if m["cancer"] == cancer_type and m["pos"] == stage["id"] and any(s in sub["title"] for s in m["sub_pos"])]
            for m in rel_milestones:
                with st.popover(f"ğŸ“š {m['name']}", use_container_width=True):
                    st.success(f"**è—¥ç‰©:** {m['drug']}\n\n**è©³ç´°æ•¸æ“š:** {m['summary']}\n\n**è‡¨åºŠè§£æ:** {m['details']}")
                    if st.button("ğŸ“Š æŸ¥çœ‹å®Œæ•´å ±å‘Š", key=f"btn_{m['name']}"):
                        st.session_state.selected_trial = m['name']
            
            # B. é¡¯ç¤ºæ‹›å‹Ÿä¸­ (ğŸ“)
            rel_trials = [t for t in ongoing_trials if t["cancer"] == cancer_type and t["pos"] == stage["id"] and any(s in sub["title"] for s in t["sub_pos"])]
            for t in rel_trials:
                label = f"ğŸ“ {t['pharma']} | {t['name']} | {t['drug']}"
                ukey = f"btn_{t['name']}_{stage['id']}_{sub['title'].replace(' ', '')}"
                with st.popover(label, use_container_width=True):
                    if st.button("ğŸ“Š é–‹å•Ÿæ·±åº¦åˆ†æå ±å‘Š", key=ukey):
                        st.session_state.selected_trial = t['name']
            st.markdown("</div>", unsafe_allow_html=True)
        st.markdown("</div>", unsafe_allow_html=True)

# --- 7. æ·±åº¦å ±å‘Šçœ‹æ¿ ---
st.divider()
all_list = milestone_db + ongoing_trials
try:
    t = next(it for it in all_list if it["name"] == st.session_state.selected_trial)
except:
    t = all_list[0]

st.markdown(f"<div class='detail-section'>", unsafe_allow_html=True)
st.markdown(f"<h2 style='color:#004D40; border-bottom:3px solid #E0E0E0; padding-bottom:10px; font-weight:900;'>ğŸ“‹ {t['name']} æ·±åº¦æ•¸æ“šåˆ†æå ±å‘Š</h2>", unsafe_allow_html=True)

if t["type"] == "Milestone":
    r1, r2 = st.columns([1, 1])
    with r1:
        st.markdown("<div style='background:#ECEFF1; border-left:10px solid #455A64; padding:15px; border-radius:10px;'><b>ğŸ“ˆ å¯¦è­‰æ‘˜è¦ (Milestone)</b></div>", unsafe_allow_html=True)
        st.write(f"**è—¥ç‰©æ–¹æ¡ˆ:** {t['drug']}")
        st.success(t['summary'])
    with r2:
        st.markdown("<div style='background:#FFF8E1; border-left:10px solid #FBC02D; padding:15px; border-radius:10px;'><b>ğŸ’¡ è‡¨åºŠè§£æ (Histology/FIGO)</b></div>", unsafe_allow_html=True)
        st.info(t['details'])
else:
    r1, r2 = st.columns([1.3, 1])
    with r1:
        st.markdown("<div style='background:#E3F2FD; border-left:10px solid #1976D2; padding:15px; border-radius:10px;'><b>ğŸ’‰ Rationale & Protocol (æ‹›å‹Ÿä¸­)</b></div>", unsafe_allow_html=True)
        st.write(f"**æ ¸å¿ƒè—¥ç‰©:** {t['drug']}")
        st.write(f"**çµ¦è—¥ç´°ç¯€:** {t.get('dosing', 'è©³è¦‹ Protocol')}")
        st.success(t['rationale'])
        
    with r2:
        st.markdown("<div style='background:#E8F5E9; border-left:8px solid #2E7D32; padding:15px; border-radius:10px;'><b>âœ… Inclusion Criteria (ç´å…¥æ¨™æº–)</b></div>", unsafe_allow_html=True)
        for inc in t.get('inclusion', []): st.write(f"â€¢ **{inc}**")
        st.markdown("<div style='background:#FFEBEE; border-left:8px solid #C62828; padding:15px; border-radius:10px; margin-top:10px;'><b>âŒ Exclusion Criteria (æ’é™¤æ¨™æº–)</b></div>", unsafe_allow_html=True)
        for exc in t.get('exclusion', []): st.write(f"â€¢ **{exc}**")
st.markdown("</div>", unsafe_allow_html=True)
